Skip to content
The Nexus
DossierENTITY

Institute for Diabetes and Obesity at Helmholtz Munich

Coverage of Institute for Diabetes and Obesity at Helmholtz Munich in the Nexus archive.

Earliest in view: May 14 · 11:00 UTCMost recent: May 14 · 11:00 UTC
Co-mentioned in this coverage
Timo D. Mullerperson1GLP-1-GIP-Lanitopic1Peter Balazsperson1Helmholtz Munichplace1Ozempictopic1
Recent coverage
  • HEALTHMay 14 · 11:00 UTCFOX NEWS
    Experimental obesity drug outperforms traditional weight-loss treatments in early research

    Researchers have developed an experimental obesity drug called GLP-1-GIP-Lani that has shown promise in early trials, outperforming traditional weight-loss treatments. The drug combines two natural hormones with PPAR activity to improve insulin sensitivity and reduce inflammation. It aims to deliver 30% weight loss with fewer side effects.